6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
described O
below O
or O
elsewhere O
in O
the O
prescribing O
information O
: O
* O
Risk O
of O
Thyroid B-NonOSE_AE
C I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
Tumors I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Pancreatitis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Use O
with O
Medications O
Known O
to O
Cause O
Hypoglycemia B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Renal B-OSE_Labeled_AE
Impairment I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Hypersensitivity B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
The O
most O
common O
adverse O
reactions O
, O
reported O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
VICTOZA O
are O
: O
nausea B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
( O
6.1 O
) O
. O

* O
Immunogenicity B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
including O
urticaria B-OSE_Labeled_AE
, O
were O
more O
common O
among O
VICTOZA-treated O
patients O
( O
0.8 O
% O
) O
than O
among O
comparator-treated O
patients O
( O
0.4 O
% O
) O
in O
clinical O
trials O
( O
6.2 O
) O
. O

EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Novo O
Nordisk O
Inc O
. O
at O
1-877-484-2869 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Common O
Adverse O
Reactions O
The O
data O
in O
Table O
1 O
are O
derived O
from O
5 O
glycemic O
control O
, O
placebo-controlled O
trials O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

These O
data O
reflect O
exposure O
of O
1673 O
patients O
to O
VICTOZA O
and O
a O
mean O
duration O
of O
exposure O
to O
VICTOZA O
of O
37.3 O
weeks O
. O

The O
mean O
age O
of O
patients O
was O
58 O
years O
, O
4 O
% O
were O
75 O
years O
or O
older O
and O
54 O
% O
were O
male O
. O

The O
population O
was O
79 O
% O
White O
, O
6 O
% O
Black O
or O
African O
American O
, O
13 O
% O
Asian O
; O
4 O
% O
were O
of O
Hispanic O
or O
Latino O
ethnicity O
. O

At O
baseline O
the O
population O
had O
diabetes B-Not_AE_Candidate
for O
an O
average O
of O
9.1 O
years O
and O
a O
mean O
HbA1cof O
8.4 O
% O
. O

Baseline O
estimated O
renal B-Not_AE_Candidate
function I-Not_AE_Candidate
was O
normal O
or O
mildly I-Not_AE_Candidate
impaired I-Not_AE_Candidate
in O
88.1 O
% O
and O
moderately O
impaired O
in O
11.9 O
% O
of O
the O
pooled O
population O
. O

Table O
1 O
shows O
common O
adverse O
reactions O
, O
excluding O
hypoglycemia B-NonOSE_AE
, O
associated O
with O
the O
use O
of O
VICTOZA O
. O

These O
adverse O
reactions O
occurred O
more O
commonly O
on O
VICTOZA O
than O
on O
placebo O
and O
occurred O
in O
at O
least O
5 O
% O
of O
patients O
treated O
with O
VICTOZA O
. O

Table O
1 O
Adverse O
reactions O
reported O
in O
> O
= O
5 O
% O
of O
VICTOZA-treated O
patients O
Placebo O
N=661 O
Liraglutide O
1.2 O
mg O
N= O
645 O
Liraglutide O
1.8 O
mg O
N= O
1024 O
Adverse O
Reaction O
( O
% O
) O
( O
% O
) O
( O
% O
) O
Nausea B-OSE_Labeled_AE
5 O
18 O
20 O
Diarrhea B-OSE_Labeled_AE
4 O
10 O
12 O
Headache B-OSE_Labeled_AE
7 O
11 O
10 O
Nasopharyngitis B-OSE_Labeled_AE
8 O
9 O
10 O
Vomiting B-OSE_Labeled_AE
2 O
6 O
9 O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
1 O
10 O
9 O
Dyspepsia B-OSE_Labeled_AE
1 O
4 O
7 O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
6 O
7 O
6 O
Constipation B-OSE_Labeled_AE
1 O
5 O
5 O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
3 O
4 O
5 O
Cumulative O
proportions O
were O
calculated O
combining O
studies O
using O
Cochran-Mantel-Haenszel O
weights O
. O

In O
an O
analysis O
of O
placebo- O
and O
active-controlled O
trials O
, O
the O
types O
and O
frequency O
of O
common O
adverse O
reactions O
, O
excluding O
hypoglycemia B-NonOSE_AE
, O
were O
similar O
to O
those O
listed O
in O
Table O
1 O
. O

Other O
Adverse O
Reactions O
Gastrointestinal O
Adverse O
Reactions O
In O
the O
pool O
of O
5 O
glycemic O
control O
, O
placebo-controlled O
clinical O
trials O
, O
withdrawals O
due O
to O
gastrointestinal B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
occurred O
in O
4.3 O
% O
of O
VICTOZA-treated O
patients O
and O
0.5 O
% O
of O
placebo-treated O
patients O
. O

Withdrawal O
due O
to O
gastrointestinal B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
mainly O
occurred O
during O
the O
first O
2-3 O
months O
of O
the O
trials O
. O

Injection O
site O
reactions O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
e.g. O
, O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
erythema O
) O
were O
reported O
in O
approximately O
2 O
% O
of O
VICTOZA-treated O
patients O
in O
the O
five O
double-blind O
, O
glycemic O
control O
trials O
of O
at O
least O
26 O
weeks O
duration O
. O

Less O
than O
0.2 O
% O
of O
VICTOZA-treated O
patients O
discontinued O
due O
to O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Hypoglycemia O
Hypoglycemia O
requiring O
the O
assistance O
of O
another O
person O
in O
placebo-controlled O
trials O
In O
5 O
glycemic O
control O
, O
placebo-controlled O
clinical O
trials O
of O
at O
least O
26 O
weeks O
duration O
, O
hypoglycemia B-OSE_Labeled_AE
requiring O
the O
assistance O
of O
another O
person O
for O
treatment O
occurred O
in O
8 O
VICTOZA-treated O
patients O
( O
7.5 O
events O
per O
1000 O
patient-years O
) O
. O

Of O
these O
8 O
VICTOZA-treated O
patients O
, O
7 O
patients O
were O
concomitantly O
using O
a O
sulfonylurea O
. O

Table O
2 O
Incidence O
( O
% O
) O
and O
Rate O
( O
episodes/patient O
year O
) O
of O
Hypoglycemia B-OSE_Labeled_AE
in O
26-Week O
Combination O
Therapy O
Placebo-controlled O
Trials O
Placebo O
Comparator O
VICTOZA O
Treatment O
Add-on O
to O
Metformin O
Placebo O
+ O
Metformin O
( O
N O
= O
121 O
) O
( O
N O
= O
724 O
) O
VICTOZA O
+ O
Metformin O
Patient O
not O
able O
to O
self-treat O
0 O
0.1 O
( O
0.001 O
) O
Patient O
able O
to O
self-treat O
2.5 O
( O
0.06 O
) O
3.6 O
( O
0.05 O
) O
Add-on O
to O
Glimepiride O
Placebo O
+ O
Glimepiride O
( O
N O
= O
114 O
) O
VICTOZA O
+ O
Glimepiride O
( O
N O
= O
695 O
) O
Patient O
not O
able O
to O
self-treat O
0 O
0.1 O
( O
0.003 O
) O
Patient O
able O
to O
self-treat O
2.6 O
( O
0.17 O
) O
7.5 O
( O
0.38 O
) O
Not O
classified O
0 O
0.9 O
( O
0.05 O
) O
Add-on O
to O
Metformin O
+ O
Rosiglitazone O
Placebo O
+ O
Metformin O
+ O
Rosiglitazone O
( O
N O
= O
175 O
) O
( O
N O
= O
355 O
) O
VICTOZA O
+ O
Metformin O
+ O
Rosiglitazone O
Patient O
not O
able O
to O
self-treat O
0 O
0 O
Patient O
able O
to O
self-treat O
4.6 O
( O
0.15 O
) O
7.9 O
( O
0.49 O
) O
Not O
classified O
1.1 O
( O
0.03 O
) O
0.6 O
( O
0.01 O
) O
Add-on O
to O
Metformin O
+ O
Glimepiride O
Placebo O
+ O
Metformin O
+ O
Glimepiride O
( O
N O
= O
114 O
) O
( O
N O
= O
230 O
) O
VICTOZA O
+ O
Metformin O
+ O
Glimepiride O
Patient O
not O
able O
to O
self-treat O
0 O
2.2 O
( O
0.06 O
) O
Patient O
able O
to O
self-treat O
16.7 O
( O
0.95 O
) O
27.4 O
( O
1.16 O
) O
Not O
classified O
0 O
0 O
`` O
Patient O
not O
able O
to O
self-treat O
'' O
is O
defined O
as O
an O
event O
requiring O
the O
assistance O
of O
another O
person O
for O
treatment O
. O

Papillary O
thyroid O
carcinoma O
In O
glycemic O
control O
trials O
of O
VICTOZA O
, O
there O
were O
7 O
reported O
cases O
of O
papillary B-OSE_Labeled_AE
thyroid I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
in O
patients O
treated O
with O
VICTOZA O
and O
1 O
case O
in O
a O
comparator-treated O
patient O
( O
1.5 O
vs O
. O
0.5 O
cases O
per O
1000 O
patient-years O
) O
. O

Most O
of O
these O
papillary B-NonOSE_AE
thyroid I-NonOSE_AE
carcinomas I-NonOSE_AE
were O
< O
1 O
cm O
in O
greatest O
diameter O
and O
were O
diagnosed O
in O
surgical O
pathology O
specimens O
after O
thyroidectomy O
prompted O
by O
findings O
on O
protocol-specified O
screening O
with O
serum O
calcitonin O
or O
thyroid O
ultrasound O
. O

Cholelithiasis O
and O
cholecystitis O
In O
glycemic O
control O
trials O
of O
VICTOZA O
, O
the O
incidence O
of O
cholelithiasis B-NonOSE_AE
was O
0.3 O
% O
in O
both O
VICTOZA-treated O
and O
placebo-treated O
patients O
. O

The O
incidence O
of O
cholecystitis B-NonOSE_AE
was O
0.2 O
% O
in O
both O
VICTOZA-treated O
and O
placebo-treated O
patients O
. O

In O
the O
LEADER O
trial O
[ O
see O
Clinical O
Studies O
( O
14.2 O
) O
] O
, O
the O
incidence O
of O
cholelithiasis B-OSE_Labeled_AE
was O
1.5 O
% O
( O
3.9 O
cases O
per O
1000 O
patient O
years O
of O
observation O
) O
in O
VICTOZA-treated O
and O
1.1 O
% O
( O
2.8 O
cases O
per O
1000 O
patient O
years O
of O
observation O
) O
in O
placebo-treated O
patients O
, O
both O
on O
a O
background O
of O
standard O
of O
care O
. O

The O
incidence O
of O
acute B-OSE_Labeled_AE
cholecystitis I-OSE_Labeled_AE
was O
1.1 O
% O
( O
2.9 O
cases O
per O
1000 O
patient O
years O
of O
observation O
) O
in O
VICTOZA-treated O
and O
0.7 O
% O
( O
1.9 O
cases O
per O
1000 O
patient O
years O
of O
observation O
) O
in O
placebo-treated O
patients O
. O

Laboratory O
Tests O
Bilirubin O
In O
the O
five O
glycemic O
control O
trials O
of O
at O
least O
26 O
weeks O
duration O
, O
mildly O
elevated B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
concentrations O
( O
elevations O
to O
no O
more O
than O
twice O
the O
upper O
limit O
of O
the O
reference O
range O
) O
occurred O
in O
4.0 O
% O
of O
VICTOZA-treated O
patients O
, O
2.1 O
% O
of O
placebo-treated O
patients O
and O
3.5 O
% O
of O
active-comparator-treated O
patients O
. O

This O
finding O
was O
not O
accompanied O
by O
abnormalities B-NonOSE_AE
in I-NonOSE_AE
other I-NonOSE_AE
liver I-NonOSE_AE
tests I-NonOSE_AE
. O

The O
significance O
of O
this O
isolated O
finding O
is O
unknown O
. O

Calcitonin O
Calcitonin O
, O
a O
biological O
marker O
of O
MTC B-NonOSE_AE
, O
was O
measured O
throughout O
the O
clinical O
development O
program O
. O

At O
the O
end O
of O
the O
glycemic O
control O
trials O
, O
adjusted O
mean O
serum O
calcitonin B-OSE_Labeled_AE
concentrations I-OSE_Labeled_AE
were I-OSE_Labeled_AE
higher I-OSE_Labeled_AE
in O
VICTOZA-treated O
patients O
compared O
to O
placebo-treated O
patients O
but O
not O
compared O
to O
patients O
receiving O
active O
comparator O
. O

Between O
group O
differences O
in O
adjusted O
mean O
serum O
calcitonin O
values O
were O
approximately O
0.1 O
ng/L O
or O
less O
. O

Among O
patients O
with O
pretreatment O
calcitonin O
< O
20 O
ng/L O
, O
calcitonin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
to O
> O
20 O
ng/L O
occurred O
in O
0.7 O
% O
of O
VICTOZA-treated O
patients O
, O
0.3 O
% O
of O
placebo-treated O
patients O
, O
and O
0.5 O
% O
of O
active-comparator-treated O
patients O
. O

The O
clinical O
significance O
of O
these O
findings O
is O
unknown O
. O

Lipase O
and O
Amylase O
In O
one O
glycemic O
control O
trial O
in O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
patients O
, O
a O
mean O
increase B-OSE_Labeled_AE
of O
33 O
% O
for O
lipase I-OSE_Labeled_AE
and O
15 O
% O
for O
amylase O
from O
baseline O
was O
observed O
for O
VICTOZA-treated O
patients O
while O
placebo-treated O
patients O
had O
a O
mean O
decrease B-NonOSE_AE
in I-NonOSE_AE
lipase I-NonOSE_AE
of O
3 O
% O
and O
a O
mean O
increase B-NonOSE_AE
in I-NonOSE_AE
amylase I-NonOSE_AE
of O
1 O
% O
. O

In O
the O
LEADER O
trial O
, O
serum O
lipase O
and O
amylase O
were O
routinely O
measured O
. O

Among O
VICTOZA-treated O
patients O
, O
7.9 O
% O
had O
a O
lipase B-OSE_Labeled_AE
value I-OSE_Labeled_AE
at O
any O
time O
during O
treatment O
of O
greater I-OSE_Labeled_AE
than I-OSE_Labeled_AE
or I-OSE_Labeled_AE
equal I-OSE_Labeled_AE
to I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
times I-OSE_Labeled_AE
the I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
compared O
with O
4.5 O
% O
of O
placebo-treated O
patients O
, O
and O
1 O
% O
of O
VICTOZA-treated O
patients O
had O
an O
amylase B-OSE_Labeled_AE
value I-OSE_Labeled_AE
at O
any O
time O
during O
treatment O
of O
greater I-OSE_Labeled_AE
than I-OSE_Labeled_AE
or I-OSE_Labeled_AE
equal I-OSE_Labeled_AE
to I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
times I-OSE_Labeled_AE
the I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
versus O
0.7 O
% O
of O
placebo-treated O
patients O
. O

The O
clinical O
significance O
of O
elevations B-NonOSE_AE
in I-NonOSE_AE
lipase I-NonOSE_AE
or O
amylase O
with O
VICTOZA O
is O
unknown O
in O
the O
absence O
of O
other O
signs O
and O
symptoms O
of O
pancreatitis B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Vital O
signs O
VICTOZA O
did O
not O
have O
adverse B-NonOSE_AE
effects I-NonOSE_AE
on I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
. O

Mean O
increase B-OSE_Labeled_AE
s O
from O
basel O
in I-OSE_Labeled_AE
e O
in O
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
of O
2 O
to O
3 O
beats O
per O
minute O
have O
been O
observed O
with O
VICTOZA O
compared O
to O
placebo O
. O

6.2 O
Immunogenicity O
Consistent O
with O
the O
potentially O
immunogenic B-NonOSE_AE
properties I-NonOSE_AE
of I-NonOSE_AE
protein I-NonOSE_AE
and I-NonOSE_AE
peptide I-NonOSE_AE
pharmaceuticals I-NonOSE_AE
, O
patients O
treated O
with O
VICTOZA O
may O
develop O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
liraglutide I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
. O

The O
detection O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
a O
ntibody B-NonOSE_AE
) I-NonOSE_AE
positivity I-NonOSE_AE
  I-NonOSE_AE
I-NonOSE_AE O
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
including O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
liraglutide I-NonOSE_AE
can O
not O
be O
directly O
compared O
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
of I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
. O

Approximately O
50-70 O
% O
of O
VICTOZA-treated O
patients O
in O
five O
double-blind O
clinical O
trials O
of O
26 O
weeks O
duration O
or O
longer O
were O
tested O
for O
the O
presence O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
liraglutide I-NonOSE_AE
antibodies I-NonOSE_AE
at O
the O
end O
of O
treatment O
. O

Low O
titers O
( O
concentrations O
not O
requiring O
dilution O
of O
serum O
) O
of O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
liraglutide I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were I-OSE_Labeled_AE
detected I-OSE_Labeled_AE
in O
8.6 O
% O
of O
these O
VICTOZA-treated O
patients O
. O

Cross B-OSE_Labeled_AE
- I-OSE_Labeled_AE
reacting I-OSE_Labeled_AE
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
liraglutide I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
to I-OSE_Labeled_AE
native I-OSE_Labeled_AE
glucagon I-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
peptide I-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
( I-OSE_Labeled_AE
GLP I-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
) O
occurred O
in O
6.9 O
% O
of O
the O
VICTOZA-treated O
patients O
in O
the O
double-blind O
52-week O
monotherapy O
trial O
and O
in O
4.8 O
% O
of O
the O
VICTOZA-treated O
patients O
in O
the O
double-blind O
26-week O
add-on O
combination O
therapy O
trials O
. O

These O
cross B-NonOSE_AE
- I-NonOSE_AE
reacting I-NonOSE_AE
antibodies I-NonOSE_AE
were O
not O
tested O
for O
neutralizing B-NonOSE_AE
effect I-NonOSE_AE
against I-NonOSE_AE
native I-NonOSE_AE
GLP I-NonOSE_AE
- I-NonOSE_AE
1 I-NonOSE_AE
, O
and O
thus O
the O
potential O
for O
clinically O
significant O
neutralization B-NonOSE_AE
of I-NonOSE_AE
native I-NonOSE_AE
GLP I-NonOSE_AE
- I-NonOSE_AE
1 I-NonOSE_AE
was O
not O
assessed O
. O

Antibodies B-OSE_Labeled_AE
that I-OSE_Labeled_AE
had I-OSE_Labeled_AE
a I-OSE_Labeled_AE
neutralizing I-OSE_Labeled_AE
effect O
on O
liraglutide O
in O
an O
in O
vitro O
assay O
occurred O
in O
2.3 O
% O
of O
the O
VICTOZA-treated O
patients O
in O
the O
double-blind O
52-week O
monotherapy O
trial O
and O
in O
1.0 O
% O
of O
the O
VICTOZA-treated O
patients O
in O
the O
double-blind O
26-week O
add-on O
combination O
therapy O
trials O
. O

Antibody B-NonOSE_AE
formation I-NonOSE_AE
was O
not O
associated O
with O
reduced O
efficacy O
of O
VICTOZA O
when O
comparing O
mean O
HbA1c O
of O
all O
antibody B-NonOSE_AE
- I-NonOSE_AE
positive I-NonOSE_AE
and O
all O
antibody B-NonOSE_AE
- I-NonOSE_AE
negative I-NonOSE_AE
patients O
. O

However O
, O
the O
3 O
patients O
with O
the O
highest O
titers O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
liraglutide I-NonOSE_AE
antibodies I-NonOSE_AE
had O
no O
reduction O
in O
HbA1c O
with O
VICTOZA O
treatment O
. O

In O
five O
double-blind O
glycemic O
control O
trials O
of O
VICTOZA O
, O
events O
from O
a O
composite O
of O
adverse O
events O
potentially O
related O
to O
immunogenicity B-OSE_Labeled_AE
( O
e.g O
. O

urticaria B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
) O
occurred O
among O
0.8 O
% O
of O
VICTOZA-treated O
patients O
and O
among O
0.4 O
% O
of O
comparator-treated O
patients O
. O

Urticaria B-OSE_Labeled_AE
accounted O
for O
approximately O
one-half O
of O
the O
events O
in O
this O
composite O
for O
VICTOZA-treated O
patients O
. O

Patients O
who O
developed O
anti B-NonOSE_AE
- I-NonOSE_AE
liraglutide I-NonOSE_AE
antibodies I-NonOSE_AE
were O
not O
more O
likely O
to O
develop O
events O
from O
the O
immunogenicity B-NonOSE_AE
events I-NonOSE_AE
composite O
than O
were O
patients O
who O
did O
not O
develop O
anti B-NonOSE_AE
- I-NonOSE_AE
liraglutide I-NonOSE_AE
antibodies I-NonOSE_AE
. O

In O
the O
LEADER O
trial O
[ O
see O
Clinical O
Studies O
( O
14.2 O
) O
] O
, O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
liraglutide I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were O
detected O
in O
11 O
out O
of O
the O
1247 O
( O
0.9 O
% O
) O
VICTOZA-treated O
patients O
with O
antibody B-NonOSE_AE
measurements O
. O

Of O
the O
11 O
VICTOZA-treated O
patients O
who O
developed O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
liraglutide I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
, O
none O
were O
observed O
to O
develop O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
to I-NonOSE_AE
liraglutide I-NonOSE_AE
, O
and O
5 O
patients O
( O
0.4 O
% O
) O
developed O
cross B-OSE_Labeled_AE
- I-OSE_Labeled_AE
reacting I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
against I-OSE_Labeled_AE
native I-OSE_Labeled_AE
GLP I-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
. O

6.3 O
Post-Marketing O
Experience O
The O
following O
additional O
adverse O
reactions O
have O
been O
reported O
during O
post-approval O
use O
of O
VICTOZA O
. O

Because O
these O
events O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
generally O
not O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

* O
Medullary B-OSE_Labeled_AE
thyroid I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Dehydration B-OSE_Labeled_AE
resulting O
from O
nausea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
and O
diarrhea B-OSE_Labeled_AE
. O

[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
and O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
* O
Increased B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
or O
worsening O
of O
chronic B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
sometimes O
requiring O
hemodialysis O
. O

[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
and O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
* O
Angioedema B-OSE_Labeled_AE
and O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

[ O
see O
Contraindications O
( O
4 O
) O
, O
Warnings O
and O
Precautions O
( O
5.6 O
) O
, O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
* O
Allergic B-NonOSE_AE
reactions I-NonOSE_AE
: O
rash B-OSE_Labeled_AE
and O
pruritus B-OSE_Labeled_AE
* O
Acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
hemorrhagic B-OSE_Labeled_AE
and O
necrotizing O
pancreatitis I-OSE_Labeled_AE
sometimes O
resulting O
in O
death O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
, O
hyperbilirubinemia B-OSE_Labeled_AE
, O
cholestasis B-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O

